Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

International journal of clinical pharmacology and therapeutics

Volumn 40, Issue 12, 2002, Pages 580-581

  Strumberg, D ^a   Voliotis, D ^a   Moeller, J G ^a   Hilger, R A ^a   Richly, H ^a   Kredtke, S ^a   Beling, C ^a   Scheulen, M E ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONIC ACID DERIVATIVE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PYRIDINE DERIVATIVE; RAF PROTEIN; SORAFENIB;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; HUMAN; MAXIMUM TOLERATED DOSE; METABOLISM; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION;

BENZENESULFONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; MAXIMUM TOLERATED DOSE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES;

EID: 0141634089     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40580     Document Type: Article

References (0)